Drug treatment of patients with functional dyspepsia is controversial but H2 receptor antagonists have been the mainstay of treatment. For patients with symptoms suggestive of dysmotility, prokinetics such as cisapride have been used. A large number of clinical trials have been unable to produce definite answers as to whether any of these treatment modalities are truly efficacious. This is partly due to the fact that the methodology and reporting of the majority of trials evaluating the symptomatic effects of H2 receptor antagonists and cisapride are severely flawed. Based on the current literature, H2 receptor antagonists may possibly have a therapeutic gain of approximately 20% over placebo. Evaluating the therapeutic gain of cisapride is more difficult but meta-analyses indicate a somewhat larger effect.
- functional dyspepsia
- H2 receptor antagonists
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Conflict of interest: This symposium was sponsored by AstraZeneca, makers of omeprazole. The author of this paper has received sponsorship for travel and an honorarium from AstraZeneca.